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Objective: Although we have previously shown that inhibition of nuclear factor κB
sensitizes non–small cell lung cancer cells to chemotherapy-mediated cell death,
the apoptotic pathways mediating this process are unknown. The purpose of this
study was to determine whether chemosensitivity after the inhibition of nuclear fac-
tor κB in non–small cell lung cancer cells is a mitochondrial and caspase-mediated
process and whether it is dependent on nuclear factor κB transcriptional activity.
Methods: Previously described H157 non–small cell lung cancer cells were treated
with gemcitabine, and DNA fragmentation was determined. Caspase 3, 6, 7, 8, and
9 activity in cytoplasmic extracts was determined fluorometrically. The mitochon-
drial permeability index and cytosolic cytochrome c levels were also determined.
The caspase inhibitor Boc-D, as well as nuclear factor κB–regulated gene products
A1, c-IAP-2, and Bcl-XL, were added to H157 cells lacking nuclear factor κB and
the degree of apoptosis assessed. All experiments were performed in triplicate, and
data significance was determined by means of analysis of variance.
Results: Non–small cell lung cancer cells lacking functional nuclear factor κB
(H157I) underwent more apoptosis after chemotherapy than vector control cells
(H157V). There was an increase in the mitochondrial permeability index and
cytochrome c release after chemotherapy in the H157I cells. H157I cells also had
more activation of caspases 3 and 9 than control cells. Inhibition of caspase activ-
ity or transfection with nuclear factor κB–regulated gene products rescued cell
death after the inhibition of nuclear factor κB.
Conclusion: Chemosensitization by means of inhibition of nuclear factor κB in
non–small cell lung cancer cells occurs through increased cytochrome c release and
caspase 3 and 9 activation. Inhibition of nuclear factor κB or its gene products in
addition to chemotherapy warrants further study as a treatment strategy in patients
with advanced-stage non–small cell lung cancer.
Although it is widely recognized that non–small cell lung cancer(NSCLC) is the number one cancer killer worldwide, there is fre-quently a nihilistic approach to treating these patients. This isbased on the advanced tumor stage at clinical presentation, aswell as the resistance of these tumors to chemotherapy and radia-tion therapy. Recent studies, however, have begun to dissect the
molecular mechanisms and cell-signaling pathways governing chemoresistance in
solid tumors, including NSCLC.1
Chemoresistance in the majority of human cancers is due to defects in apopto-
sis-signaling pathways.2 After exposure to genotoxic stress, programmed cell death
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(or apoptosis) is mediated by activation of a cascade of
intracellular proteases called caspases.3 Proapoptotic sig-
nals, such as chemotherapy or radiation, appear to activate
an initiator caspase, such as caspase 8 or 9, which then
cleaves downstream effector procaspases (caspases 3, 6,
and 7) that ultimately lead to the morphologic changes char-
acteristic of apoptosis.3,4
Before any type of cell death (apoptosis or necrosis),
there is a dissipation of the mitochondrial membrane poten-
tial with subsequent release of apoptogenic proteins, such
as cytochrome c and apoptosis-inducing factor.4,5 Once the
mitochondrial membrane barrier is lost, the metabolic con-
sequences at the bioenergetic level, the loss of redox homeo-
stasis, and the perturbation of ion homeostasis all contribute
to cell death.4 In fact, it is the pivotal role of the mitochon-
drion in cell death that has invalidated the hypothesis that
caspase activation is always required for apoptosis.
We and others have recently identified that activation of the
transcription factor nuclear factor (NF) κB is a novel mecha-
nism of chemoresistance in NSCLC and other tumors.6,7 The
antiapoptotic effects of chemotherapy-induced NF-κB activa-
tion are thought to be mediated by gene products transcrip-
tionally regulated by NF-κB. NF-κB has been shown to
regulate the expression of several antiapoptotic gene products,
including cIAP-2, a member of the inhibitor of apoptosis pro-
tein family, as well as the prosurvival Bcl-2 family members
Bcl-XL and A1 (also called Bfl-1).8-10
Recognition that NF-κB is a mediator of chemoresis-
tance in human cancer has prompted several investigators to
evaluate whether inhibition of NF-κB activation might sen-
sitize tumors to chemotherapy.6,7 We have shown that inhi-
bition of NF-κB combined with chemotherapy in NSCLC
cells sensitizes the tumors to die as evidenced by an
increase in apoptosis.6 Although modulation of NF-κB may
be an attractive molecular target in NSCLC, the exact apop-
totic cascade or cascades activated when NF-κB is inhibited
is unknown.
The purpose of this study was to determine the specific
apoptotic cell-signaling pathways activated in NSCLC cells
treated with chemotherapy after the inhibition of NF-κB. A
well-established and previously described in vitro model of
NF-κB inhibition in NSCLC was used to determine this.6
We also sought to determine whether overexpression of NF-
κB–regulated antiapoptotic gene products would rescue cell
death after the inhibition of NF-κB and treatment with
chemotherapy, thus confirming that NF-κB is a prime medi-
ator of chemoresistance in NSCLC.
Materials and Methods
Cell Culture
The human NSCLC cell line NCI-H157 (American Type Culture
Collection, Manassas, Va) was incubated at 37°C in RPMI-1640
media, supplemented with 10% fetal bovine serum and antibiotics
(GibcoBRL Life Technologies, Rockville, Md). Cells were cul-
tured to 100% confluence, trypsinized, and plated at a seeding
density of 2 × 106 cells per 100-mm dish.
Generation of Stably Expressing Dominant-Negative
NF-κB Cell Lines
Generation of H157 cells stably expressing the dominant-negative
inhibitor of NF-κB, IκBα-SR, have been previously described in
detail.6 Briefly, the IκBα-SR sequesters NF-κB in the cytoplasm,
thus inhibiting its nuclear translocation and preventing transcrip-
tion of NF-κB–dependent gene products. Clones expressing the
IκBα-SR were pooled and renamed H157I, and vector control
cells were renamed H157V. As we have previously shown, these
H157I cells do not translocate NF-κB to the nucleus or transcribe
any NF-κB–regulated gene products.6
Measurement of Gemcitabine-induced DNA
Fragmentation
H157V or H157I cells were plated on sterile glass cover slips con-
tained in the individual wells of a 6-well culture dish, grown to
75% confluency, and treated with gemcitabine (1 µmol/L; Eli Lilly
and Co, Indianapolis, Ind) for 72 hours. DNA fragmentation was
measured by means of terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) assay, according to
the manufacturer’s instructions (Roche Diagnostics Corporation,
Indianapolis, Ind).
Nucleosome formation, an indicator of apoptotic DNA fragmen-
tation, was measured with the Cell Death Detection ELISA (Roche
Molecular Biochemical, Indianapolis, Ind). H157I and H157V cells
were treated with gemcitabine for selected time periods. All subse-
quent steps were performed either at 4°C or on ice. Cells were har-
vested by scraping, washed in ice-cold PBS by means of
centrifugation at 1000g, and solubilized for 2 minutes in ice-cold
RIPA buffer (150 mmol/L NaCl, 25 mmol/L Tris-HCl, 5 mmol/L eth-
ylenediamine tetraacetic acid [EDTA], 1% IGEPAL CA630, and
0.5% deoxycholate [pH 8.0]) containing 100 µmol/L phenylmethyl-
sulfonyl fluoride and 1 mmol/L dithiothreitol. Insoluble cell compo-
nents were placed in pellets by means of centrifugation. After a
determination of protein content in the supernatant (BCA Protein
Assay; Pierce, Rockford, Ill), appropriate volumes of cell lysate and
RIPA were combined in individual wells of an ELISA plate for a final
lysate concentration of 1 µg/20 µL total volume. Samples were then
incubated with biotinylated antihistone antibody and POD-labeled
anti-DNA antibody for 2 hours at 37°C in a streptavidin-coated
ELISA plate. The plate was then washed 3 times, and a colorimetric
substrate was added and further incubated. The absorbance, measured
spectrophotometrically at 405 nm, gave a measure of nucleosome for-
mation, with absorbance at 490 nm used as a reference. Experiments
were performed in triplicate and are expressed as optical density units
per microgram ± SD. The significance of the data was determined
with a paired, 2-tailed Student t test.
Measurement of Mitochondrial Permeability Changes
(∆ψm)
Cells were treated with gemcitabine (1 µmol/L) for up to 48 hours,
and the culture medium was aspirated. Fifty microliters of a solu-
tion containing 5 µg/mL JC-1 dye (Trevigen DePsipher,
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Gaithersburg, Md) in 1× reaction buffer was added to each well,
and the plate was incubated for 15 minutes at 37°C . The dye solu-
tion was then aspirated and replaced with 1× reaction buffer, and
the fluorescence in each well was read on a 96-well fluorometer,
with an excitation wavelength of 490 nm. The JC-1 dye (5,5′,6, 6′,
tetrachloro-1,1′,3,3′ tetraethylbenzmidazolyl carbocyanin iodide)
aggregates and fluoresces maximally at 590 nm when ∆ψm is main-
tained in the mitochondria but remains monomeric, and fluoresces
at 530 nm when ∆ψm is disrupted. Changes in mitochondrial per-
meability were measured as the fluorescence ratio of 530 to 590 nm
in each well to account for potential differences in absolute fluo-
rescence between individual wells. These experiments were per-
formed in triplicate, with results normalized to untreated H157V
cells. Significance of the data was determined by using a paired, 2-
tailed Student t test and analysis of variance (ANOVA) with the
Bonferroni multiple comparison when applicable.
Measurement of Cytochrome c Extravasation
Mitochondria-free cytosolic preparations were prepared according
to previously established techniques.11 Because this is a mito-
chondrial-free preparation, any cytochrome c measured above
basal levels is a result of extravasation from the mitochondria.
Briefly, H157I and H157V cells were treated with gemcitabine
for 0, 12, 24, or 48 hours. Cells were harvested by scraping, washed
in PBS, centrifuged at 200g for 5 minutes, and triturated 10 times in
hypotonic lysis buffer (220 mmol/L mannitol, 68 mmol/L sucrose,
50 mmol/L PIPES-KOH, 50 mmol/L KCl, 5 mmol/L EDTA, 2
mmol/L MgCl2, 1 mmol/L dithiothreitol (pH 7.4), 100 µmol/L
phenylmethylsulfonyl fluoride, 5 µg/mL aprotinin, 5 µg/mL leu-
peptin, and 2.5 µg/mL pepstatin). After incubation on ice, the sus-
pension was centrifuged at 200g for 5 minutes, and the supernatant
was transferred to a separate tube. The samples were centrifuged at
16,000g, transferred to a fresh tube, and stored at 80°C.
Mitochondria-free cytosolic preparations were electrophoresed
on 12% sodium dodecylsulfate-polyacrylamide gels and trans-
ferred to nitrocellulose membranes (Schleicher & Schuell, Keene,
NH). Purified cytochrome c was also included as a positive con-
trol. Western blots were probed for cytochrome c with a primary
antibody to cytochrome c (BD Pharmingen, San Diego, Calif).
After incubation with horseradish peroxidase–conjugated anti-
mouse secondary antibody and enhanced chemiluminescence
(Amersham, Cleveland, Ohio), those bands identified as
cytochrome c were quantitated by means of laser densitometry
analysis of the autoradiograms. Each blot was stripped of anti-
cytochrome c antibody and reprobed for β-tubulin. These experi-
ments were performed in triplicate. The data were normalized first
to β-tubulin and then to basal (time zero) release, and densitome-
try analysis was performed for each separate experiment. Data sig-
nificance was determined by means of ANOVA with Bonferroni
multiple comparisons.
Measurement of Gemcitabine-induced Caspase Activity
The caspase assay used in these studies measures the cleavage of
a fluorometric moiety from an oligopeptide containing a cleavage
site specific for individual caspases. Cell lysates prepared for the
nucleosome assay above were added to a fluorometry plate such
that each well contained identical amounts of protein. Seventy-five
microliters of 4/3× caspase assay buffer containing 300 µg/mL
oligopeptide-linked fluorophore was added, resulting in a solution
containing cell lysate and fluorophore-conjugated caspase sub-
strate in 1× caspase assay buffer (10 mmol/L PIPES, 2 mmol/L
EDTA, 0.1% CHAPS, and 5 mmol/L dithiothreitol [pH 7.4]). The
oligopeptide caspase substrates used were as follows: caspase 3,
DEVD-AFC; caspase 6, VEID-AFC; caspase 7, VDQVDGW[K-
DNP]; caspase 8, IETD-AFC; and caspase 9, LEHD-AFC
(Calbiochem, San Diego, Calif).
Caspase activity was then measured kinetically as the genera-
tion of fluorescence over 1 hour at the appropriate excitation and
emission wavelengths (AFC: excitation = 400 nm and emission =
505 nm; DNP: excitation = 320 nm and emission = 390 nm).
These values were converted to units of enzymatic activity by
means of comparison with standard concentrations of AFC or
DNP normalized to 1 µg of protein and expressed as picomoles
per hour per microgram of lysate. The data are expressed as enzy-
matic units, and the significance was determined by means of
ANOVA, followed by Bonferroni multiple comparisons.
The broad-spectrum caspase inhibitor Boc-D-fmk (7.5 µmol/L;
Calbiochem, San Diego, Calif) was added to the culture media of both
the H157V and H157I cells 1 hour before exposure to gemcitabine to
determine whether an increase in caspase activation was responsible
for chemosensitization after the inhibition of NF-κB. Nucleosome
and caspase 3 activation were then analyzed, as described above.
Enhanced Cell Survival After Expression of NF-
κB–regulated Proteins
H157 cells were plated at a density of 1.5 × 106 cells per milliliter,
and the following day, cells were infected with 150 pfu/cell IκBα-
SR adenovirus. We have previously shown near 100% infectivity
of the IκBα-SR using this approach (data not shown). Twenty-four
hours after infection, transient transfections with PolyFect
(Qiagen Inc, Valencia, Calif) were performed with expression
plasmids encoding for green fluorescent protein (GFP), as well as
the NF-κB–regulated proteins A1, Bcl-XL, or c-IAP-2. This
cotransfection was performed at a GFP/NF-κB-regulated protein
ratio of 1:5. Accordingly, GFP-positive cells also expressed the
proteins, A1, Bcl-XL, or c-IAP-2. Expression of these proteins was
confirmed by means of Western blot analysis. Twenty-four hours
after transfection, cells were treated with 1 µmol/L gemcitabine.
GFP-positive cells were counted in 3 separate fields by using an
inverted fluorescent microscope the following day. Cell lysates
were subjected to sodium dodecylsulfate-polyacrylamide gel elec-
trophoresis and probed for A1 (FLAG-Ab; Sigma, St Louis, Mo),
Bcl-XL (Transduction Laboratories, Lexington, Ky), or c-IAP-2
(myc-Ab, Transduction Laboratories). Cell survival was calculated
with untreated vector control cells and defined as 100% survival.
Experiments were performed in triplicate, data were expressed as
the percentage of surviving cells, and significance was determined
by means of ANOVA with Bonferroni multiple comparisons.
Results
Inhibition of NF-κB and Chemotherapy: Effects on
DNA Fragmentation
As shown in Figure 1, H157V cells treated with gem-
citabine did not display the common signs of apoptosis,
Jones et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 2   313
TX
ET
CS
P
G
TS
CH
D
G
TS
ED
IT
O
RI
A
L
such as TUNEL staining and DNA condensation. In con-
trast, NF-κB–deficient H157I cells treated with gemc-
itabine were strongly TUNEL positive and, on
phase-contrast microscopy, demonstrated the typical apop-
totic morphology of nuclear condensation and fragmenta-
tion.
The time course of apoptosis after chemotherapy is
shown in Figure 2. The H157I cells demonstrated increased
DNA fragmentation, as measured by means of nucleosome
formation, compared with that of the vector control
(H157V). This effect became important after 12 hours (P =
.01) of treatment and continued through 24 (P = .004), 36
(P = .004), and up to 48 (P = .007) hours. Thus gemcitabine
treatment of NCI-H157 NSCLC cells lacking functional
NF-κB resulted in a time-dependent, 3-fold induction of
DNA fragmentation, as measured by nucleosome forma-
tion, compared to vector controls.
Mitochondrial Permeability and Cytochrome c Release
NF-κB–deficient H157I cells displayed increased basal
mitochondrial permeability (∆ψm) compared with H157V
cells (P = .006; Figure 3, A). Furthermore, treatment of
Figure 1. DNA fragmentation was measured by means of TUNEL
staining of NF-κB–deficient (H157I) and vector control (H157V)
human NSCLC cells after a 72-hour treatment with gemcitabine (1
µmol/L). Shown below the TUNEL figures are the corresponding
phase-contrast images. FITC, Fluorescein isothiocyanate.
Figure 2. After treatment with gemcitabine (1 µmol/L) in H157I and
H157V cells, DNA fragmentation over time was measured by
means of nucleosome formation. *Differences when comparing
H157I cells with H157V cells. OD, Optical density.
Figure 3. Panel A demonstrates changes in mitochondrial mem-
brane potential (∆ψm) evoked by means of gemcitabine in H157I
and H157V cells. ∆ denotes differences in basal (time 0) ∆ψm
between H157I and H157V cells. *Important changes in ∆ψm from
basal. Panel B illustrates the degree of cytochrome c extravasa-
tion from mitochondria in H157I and H157V cells after gemcitabine
administration. A representative Western blot of cytochrome c
content in mitochondria-free cytoplasmic extracts is shown
above the bar graph. *Differences compared with basal levels.
A
B
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H157I cells with gemcitabine resulted in increases in ∆ψm
at 12 (P = .001) and 24 (P = .001) hours. A small increase
(P = .01) in ∆ψm was seen after 48 hours of gemcitabine in
H157V cells.
A corollary experiment evaluating the mitochondrial
release of cytochrome c into the cytosol is shown in Figure
3, B. In vector control H157V cells, there was no
cytochrome c extravasation above basal levels, although
there appeared to be a slight increase at 48 hours. In con-
trast, gemcitabine caused mitochondrial cytochrome c
extravasation in the NF-κB–deficient H157I cells. This
increase in cytosolic cytochrome c became apparent at 24
hours and was even more pronounced (P = .04) after 48
hours of treatment with gemcitabine. Thus changes in the
∆ψm appear to correlate with an increased mitochondrial
leakage of cytochrome c, and perhaps more importantly,
these observations were more pronounced in the cells lack-
ing NF-κB.
Gemcitabine-induced Caspase Activation
As shown in Figure 4, there was a time-dependent increase
in the activity of caspases 9 and 3 in the H157I NSCLC
cells. Caspase 9 activity was elevated 36 (P = .01) and 48
(P = .001) hours after chemotherapy, whereas caspase 3
activity was increased above basal levels at 24 (P = .04), 36
(P = .001), and 48 (P = .001) hours. However, there were no
significant increases in caspases 6, 7, and 8 after
chemotherapy. There was also no activation of any caspases
in the vector control cell line (H157V) when compared with
the H157I cells (data not shown). Thus in this NSCLC cell
line, chemotherapy appears to involve increased activity of
specific initiator and effector caspases when NF-κB is
inhibited.
Figure 5 demonstrates that the addition of the broad-
spectrum caspase inhibitor Boc-D-fmk rescued cell death in
cells lacking NF-κB. In H157I cells gemcitabine caused
increases in caspase 3 activity (P = .001) and DNA frag-
mentation (P = .001) that was reversed in the added pres-
ence of Boc-D (P = .001 for both caspase 3 activity and
DNA fragmentation). In H157V cells addition of the cas-
pase inhibitor alone led to a significant (P = .04) decrease
in caspase 3 activity. Gemcitabine caused an increase in
caspase 3 activity (P = .001) and DNA fragmentation (P =
.001), whereas the further addition of caspase inhibitor led
to a decrease in both caspase 3 activity (P = .001) and DNA
fragmentation (P = .001). Therefore the caspase inhibitor
caused the expected abrogation of gemcitabine-induced
caspase 3 activity, as well as a concomitant inhibition of
DNA fragmentation (Figure 5, A). This was true for both
H157V (Figure 5, B) and H157I cells, although the overall
levels of both caspase 3 activity and DNA fragmentation
were greater in H157I cells.
Figure 4. A time course of gemcitabine-induced caspase activa-
tion in H157I cells is shown above. Note that caspases 3 and 9 are
the only caspases activated to any significant degree.
*Differences compared with basal activity.
Figure 5. Gemcitabine-induced DNA fragmentation depends on
caspase activity. H157I and H157V cells were pretreated for 1 hour
with a broad-spectrum caspase inhibitor (Boc-D-fmk, 7.5 µmol/L)
before addition of gemcitabine (1 µmol/L). *Increases above basal
activity; †important differences between gemcitabine plus Boc-D
and gemcitabine alone. OD, Optical density.
A
B
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Enhanced Cell Survival After Expression of NF-
κB–regulated Proteins
Parental H157 cells previously infected with an adenovirus
encoding the IκBα-SR were treated with gemcitabine, and
a 50% reduction in cell survival at 24 hours after treatment
(P = .001 vs untreated cells), as measured by GFP positiv-
ity, was noted (Figure 6). This cell death was significantly
reversed by overexpression of the NF-κB–regulated gene
products A1 (P = .01), Bcl-XL (P = .04), and c-IAP-2 (P =
.001) alone or when expressed in combination (P = .001).
Western blot analysis confirmed the expression of A1, Bcl-
XL, and c-IAP-2 in the appropriate transfected cells. Thus
overexpression of these cell-survival proteins rescued cell
death after the loss of NF-κB, suggesting that NF-κB is an
important mediator of chemotherapy-induced cell death.
Discussion
The current paradigm for treating advanced-stage NSCLC
involves chemotherapy, despite the fact that response rates
remain poor, partial, and short lived. Unfortunately,
chemoresistance in NSCLC is relatively unaffected by dose,
delivery interval, or specific agents.12 Thus the clinical
problem of chemoresistance in NSCLC is one in which an
improved understanding of tumor cell–signaling mecha-
nisms governing cell survival and death may lead to
improved treatment strategies.
As discussed, we have previously shown that in NSCLC
chemotherapy-induced activation of NF-κB is a novel
mechanism of chemoresistance and that inhibition of NF-
κB chemosensitizes the cells to die.6 As shown in Figures 1
and 2, inhibition of NF-κB results in morphologic changes
characteristic of apoptosis, and there is a significant time-
dependent increase in DNA fragmentation at the doses of
gemcitabine studied. We have not varied the dose of gem-
citabine investigated, preferring to use a clinically relevant
dose,13 but higher dosing or lower doses at repeated inter-
vals may result in an even further chemosensitization.
It is becoming increasingly clear that the process of apop-
tosis is complex and regulated (both positively and nega-
tively) by a number of different molecules and signaling
pathways. Therefore apoptotic pathways are likely to be
divergent and dependent, in part, on the type of genotoxic
compound and on the type of tumor treated. This study sug-
gests that when NF-κB is inhibited, NSCLC cells treated
with chemotherapy undergo apoptosis through a mitochon-
drial-mediated process. This is evidenced by increases in the
mitochondrial permeability index and extravasation of
cytochrome c into the cytosol when NF-κB is inhibited and
cells are treated with chemotherapy. This suggests that NF-
κB transcriptionally regulates gene products that decrease or
alter the mitochondrial membrane permeability. Several stud-
ies have identified NF-κB–regulated genes that may affect
mitochondrial permeability, including the antiapoptotic Bcl-
2 family members A1 and Bcl-XL.9,10 Both of these proteins
are thought to physically interact with and inhibit the perme-
ability transition pore complex, thus preventing the efflux of
proteins necessary for the induction of apoptosis and cell
death.4 The importance of drugs designed to inhibit mito-
chondrial membrane depolarization is well known and is the
focus of current drug studies looking to exploit its role in the
cell death pathway. Drugs, such as betulanic acid,
lonidamine, and CD437, when combined with either
chemotherapy or irradiation, may significantly affect tumor
cell resistance to these standard types of treatment.4
Another important component of the cellular apoptotic
machinery is caspase activation. Joseph and colleagues14
recently identified the presence of procaspases 2, 3, 7, 8,
and 9 in multiple chemotherapy-naive NSCLC cell lines,
which is a distinctly different list of procaspases than those
present in small cell lung cancer.14 Our study shows that in
the absence of NF-κB, caspase activation is specific and,
within the sensitivity of the assay, limited to caspases 3 and
9 (Figure 4). It appears, in our study, that caspase 9 is only
increased slightly before there is notable caspase 3 activa-
Figure 6. Overexpression of A1, Bcl-XL, and c-IAP-2 rescue cell
death in NSCLC cells after inhibition of NF-κB and chemotherapy.
Shown above the graph is the Western blot confirming expression
of the proteins. *Important decrease in survival compared with
untreated vector control cells; †important difference compared
with cells treated with gemcitabine only. V, Vector control; N, NF-
κB–regulated gene product.
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tion. This may be explained by the fact that the amount of
caspase 9 activation required to activate caspase 3 and sub-
sequently amplify the caspase cascade is unknown.
Whether this activation of caspase 9 is biologically signifi-
cant is unknown because specific pharmacologic inhibitors
of caspase 9 are not available. Caspase 3 activation did cor-
relate with the rise in nucleosome formation (Figure 2),
which begins to occur approximately 12 hours after treat-
ment. The importance of caspases in the NSCLC cells that
lack NF-κB is underscored by the fact that caspase activa-
tion was required for chemotherapy-induced apoptosis
(Figure 5).
Previous studies have suggested that caspase 8 is acti-
vated in chemotherapy-induced cell death in NSCLC,15,16
but we found no evidence of this in our study. Initial stud-
ies suggested that chemotherapy-induced apoptosis
occurred through the Fas death receptor pathway,17 with
subsequent caspase 8 activation. We and others have shown
in NSCLC cell lines that chemotherapy does not use the
Fas/FasL pathway for cell death, irrespective of the tumor’s
NF-κB functional status.18,19
Although it is clear that NF-κB is required for NSCLC
cell survival after chemotherapy, this observation was fur-
ther confirmed by the addition of several NF-κB–regulated
gene products that rescued cell death after the loss of tran-
scriptionally active NF-κB. Wang et al8 and others9 identi-
fied both c-IAP-2 and A1 as NF-κB–regulated gene
products involved in cell survival. In addition, Chen and
colleagues10 have shown that NF-κB directly regulates the
expression of Bcl-XL. These findings are supported by this
study, which demonstrates that transient overexpression of
these proteins rescues cell death in cells lacking NF-κB,
thus confirming the importance of these proteins as media-
tors of tumor cell survival. Although it is unknown whether
NSCLC overexpresses A1 or c-IAP-2 relative to normal
lung tissue, it is known that the majority of these tumors
express both Bcl-XL mRNA and protein.20 Like inhibiting
NF-κB, this has important clinical applications because pre-
clinical studies with Bcl-XL antisense oligonucleotide
strategies have been shown to be effective inducers of apop-
tosis in NSCLC.21 Thus inhibition of NF-κB followed by
chemotherapy may be an attractive treatment option for
tumors, such as NSCLCs, which overexpress Bcl-XL.
Although this study has demonstrated signaling mecha-
nisms involved in chemotherapy-induced apoptosis after the
loss of NF-κB in NSCLC cells, there are certain limitations
to its design. First, this study was designed to dissect spe-
cific cell-signaling pathways involved in apoptosis after the
loss of NF-κB in a well-established NSCLC cell line. As
such, it is an in vitro study and lacks corollary in vivo data.
Proof-of-principle studies like this are best suited to an in
vitro analysis, with the findings subsequently applied in
vivo. This in vivo application is currently undergoing eval-
uation in our laboratory. Second, use of stably transfected
cell lines raises issues of clonal-dependent signaling. This
criticism is abrogated, in part, by use of pooled instead of
isolated clones, as well as induction of chemosensitivity by
means of adenoviral-mediated delivery of the dominant-
negative inhibitor of NF-κB (Figure 6). Adenoviral delivery
of the IκBα-SR resulted in nearly identical chemosensitiza-
tion to that seen with our stably transfected cell lines.6 In
our experience clonal pooling is less likely to lead to incon-
sistent signal transduction pathway identification compared
with the use of isolated clones. Third, a single NSCLC cell
line was used in this study, and it is possible that other
NSCLC cell lines may have different chemotherapy-
induced NF-κB cell-signaling pathways. However, all cell
lines studied in our laboratory to date act in a similar fash-
ion (D. R. Jones, unpublished data). Although a solitary
strategy to inhibit NF-κB was used in these experiments, it
has been shown that adenoviral-mediated, as well as phar-
macologic, inhibition of NF-κB results in chemosensitiza-
tion of a number of solid tumors, both in vivo and in
vitro.7,8 Finally, although it is known that other chemother-
apeutic agents (paclitaxel [Taxol], cisplatin, and etoposide)
activate NF-κB,22 it is possible that these other agents may
have different proapoptotic mechanisms of action after the
inhibition of NF-κB.
In conclusion, this study has shown that inhibition of
NF-κB chemosensitizes NSCLC cells to undergo apoptosis
through a mitochondrial and caspase-mediated process.
This work suggests that chemotherapy, when combined
with inhibition of NF-κB, its related prosurvival gene prod-
ucts, or both, may be an important molecular target for
patients with advanced-stage NSCLC. Future studies are
needed to identify novel pharmaceutical agents that directly
affect the cell-survival pathways regulated by NF-κB, in
order that appropriate preclinical and phase I studies can be
initiated.
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Discussion
Dr Stephen G. Swisher (Houston, Tex). There is some contro-
versy in the literature about whether NF-κB induces or inhibits
apoptosis. Some reports argue that increased NF-κB can actually
induce apoptosis in some cell lines. I was wondering if you had
looked at various cell lines or what you thought the mechanism
might be? Did you also look at normal cells because the therapeu-
tic index between cancer and normal cells is also important for
therapy?
Dr Jones. Those are both very good questions. It is true that
there is some controversy in the literature regarding the role of NF-
κB in apoptosis. In all of the NSCLC cell lines, we have investi-
gated NF-κB activation results in prosurvival cell signals. Second,
members of the NF-κB family of proteins are overexpressed in
approximately 80% of NSCLCs by means of Western blot analy-
sis in contrast to normal pulmonary parenchyma. This suggests
that there is a difference in NF-κB expression between the tumor
and the adjacent normal lung tissue.
Dr David H. Harpole, Jr (Durham, NC). Through my investi-
gation of your subject matter, I found an article from investigators
in Japan describing the use of calcium-channel blockers, and it
appears from their cell-line data that nifedipine actually works
quite well in blocking NF-κB. Are you looking at that as one of the
possible ways of doing this?
Dr Jones. I have not specifically looked at calcium signaling in
this model, but one of my colleagues who is interested in prostate
carcinoma is looking closely at inhibition of calcium to achieve
the same objectives discussed today. Therefore we have not evalu-
ated calcium or calcium-channel blockers, but I am aware of this
pathway.
